News

BioAdaptives Expands Leadership with Reed Harris Appointment

BioAdaptives Expands Leadership with Reed Harris Appointment

Exciting New Addition to BioAdaptives Leadership

BioAdaptives Inc. (OTC: BDPT), a well-regarded name in the biotechnology sector, has made headlines by welcoming Reed Harris to its Board of Advisors. With a rich experience that spans more than four decades in leadership, athlete development, and business management, Harris's commitment to innovation aligns seamlessly with the goals of BioAdaptives.

Reed Harris's Professional Background

As the Senior Vice President of Athlete Development and Marketing at the Ultimate Fighting Championship (UFC), Reed Harris has carved out a notable career that integrates martial arts prowess with business acumen. He has established a legacy that combines his experience in building organizations and giving back to the community through various charitable initiatives.

Harris is well-known for founding World Extreme Cagefighting (WEC), a highly successful MMA promotion that has captured audiences both in the U.S. and globally, broadcasting in countries including Canada, Brazil, Mexico, and Australia. His decision to sell WEC to the UFC in 2006 and subsequent management of the organization until its merger in 2012 underscores his significant impact on the mixed martial arts industry.

Impact of Reed Harris's Appointment

In his role within BioAdaptives, Harris will collaborate closely with the marketing team to help introduce and promote innovative products such as Xcellera. Xcellera stands out as a cutting-edge stem cell activator that has been validated through randomized, double-blind, placebo-controlled human clinical trials. This product has shown an impressive average increase of 268.8% in circulating stem cells within a span of 28 days, offering benefits for tissue repair, immune support, anti-aging, and cardiovascular health.

Vision for the Future

Jim Keener, CEO of BioAdaptives, expressed enthusiasm about the valuable insights that Harris will bring to the company. Keener noted, "We are excited to welcome Reed Harris to our Board of Advisors. Reed’s exceptional leadership, business acumen, and dedication to athlete development and community service align perfectly with our mission to deliver innovative health and wellness solutions. His deep experience building and managing successful organizations and his passion for helping others make him an invaluable asset to BioAdaptives as we expand our reach and impact."

BioAdaptives: A Commitment to Quality Health Solutions

BioAdaptives, Inc. is dedicated to being at the forefront of the health and wellness industry, focusing on developing and marketing nutraceutical and wellness products. The company combines the power of natural ingredients with advanced scientific methods to create solutions that enhance the quality of life for its customers. Their mission is deeply rooted in improving health and vitality, making their products an integral part of everyday health practices.

Contact and Product Information

For those interested in learning more about Xcellera™ Stem Cell Activator and other offerings from BioAdaptives, the company's official website provides comprehensive details. They are committed to ensuring that every potential customer understands the benefits and applications of their groundbreaking products.

Frequently Asked Questions

1. Who is Reed Harris?

Reed Harris is the Senior Vice President of Athlete Development and Marketing at UFC, with over 40 years of experience in leadership and business management.

2. What position has Reed Harris taken at BioAdaptives?

He has joined the Board of Advisors at BioAdaptives, bringing his expertise and knowledge to help the company innovate its health solutions.

3. What is Xcellera?

Xcellera is a stem cell activator developed by BioAdaptives, shown in trials to significantly increase circulating stem cells, which supports various health benefits.

4. What is BioAdaptives' focus?

BioAdaptives focuses on developing and marketing wellness products that harness natural ingredients combined with cutting-edge science to improve health and vitality.

5. How can I contact BioAdaptives?

You can reach BioAdaptives via their official website or by contacting Emily Harrison, IR Coordinator, at (702)-659-8829 for inquiries.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 11

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 7

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 7

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
NARUTO Card Game Set for June 2027 Global Launch

Updated Category News Views 11

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 4

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 10

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 6

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 10

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 5

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading

Top 5 Most Recently Viewed Articles

Chart Industries Transitions to New Leadership in Upcoming Merger

Updated Category News Views 231

Chart Industries Announces Leadership Change Chart Industries (NYSE: GTLS) is taking significant steps toward a future transition as CEO Jill Evanko has announced plans to assume a senior advisor role starting in early 2026. This change comes as she prepares to take on a new executive opportunity within a privately owned company. Evanko has been essential in steering the...

Continue Reading
Understanding Debtors: Insights into Realkredit Danmark A/S

Updated Category News Views 299

Understanding Debtors: Key Insights from Realkredit Danmark A/S At the heart of any effective financial institution is a reliable understanding of its debtors. Realkredit Danmark A/S, a prestigious name in the financial landscape, recently made available a detailed breakdown of its debtors. This information is crucial for various stakeholders, including investors,...

Continue Reading
Cryptocurrency Market Update: Bitcoin Droops under $59K with ETF Inflows Soaring

Updated Category News Views 148

Bitcoin's Recent Performance The cryptocurrency market has been lively lately, especially with Bitcoin recently falling below the $59,000 threshold. Investors had been optimistic, especially since the cryptocurrency saw a remarkable $436 million in net ETF inflows just last week. This significant influx signals that institutional interest in cryptocurrencies is still...

Continue Reading
Enhancing Specialized Care for ARFID Treatment with Emily Program

Updated Category News Views 169

Introduction to The Emily Program and ARFID The Emily Program is making significant strides in specialized care for individuals with Avoidant/Restrictive Food Intake Disorder (ARFID). This condition, often misunderstood, has recently begun to garner more attention from healthcare experts. In response to this need, The Emily Program is offering advanced treatment...

Continue Reading
Investigation of Alleged Securities Fraud at 3D Systems Unfolds

Updated Category News Views 167

Overview of Legal Actions Against 3D Systems Corporation Recently, investors in 3D Systems Corporation have found themselves entangled in a potential securities fraud lawsuit. This case serves as a cautionary tale, highlighting the importance of transparency and integrity in corporate communication. The allegations stem from assertions that the company made misleading...

Continue Reading